Rule 3.19A.2

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| Name of entity Antisense Therapeutics Limited (ASX: ANP) |  |
|--|--|
| ABN 41 095 060 745                                       |  |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director    | Robert W Moses   |
|---------------------|------------------|
| Date of last notice | 04 December 2019 |

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest  | Direct                      |                                       |                           |
|--|-----------------------------|---------------------------------------|---------------------------|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | -                           |                                       |                           |
| Date of change   | 16 December 2019            |                                       |                           |
| No. of securities held prior to change   | Direct<br>Indirect<br>Total | Shares<br>8,000,000<br>-<br>8,000,000 | Options 618,888 - 618,888 |
| Class  | Ordinary sh                 | nares                                 |                           |
| Number acquired  | 618,888                     |                                       |                           |
| Number disposed  | Nil                         |                                       |                           |
| Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation   | \$49,511                    |                                       |                           |

<sup>+</sup> See chapter 19 for defined terms.

| No. of securities held after change   |             |                  |         |
|---|-------------|------------------|---------|
|   |             | Shares           | Options |
|   | Direct      | 8,618,888        | -       |
|   | Indirect    | -                | -       |
|   | Total       | 8,618,888        | -       |
|   | _           |                  | _       |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Exercise of | Listed Options ( | ANPOB)  |

## Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract  | N/A |
|---|-----|
| Nature of interest  | N/A |
| Name of registered holder (if issued securities)  | N/A |
| Date of change  | N/A |
| No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| Interest acquired   | N/A |
| Interest disposed   | N/A |
| Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation   | N/A |
| Interest after change   | N/A |

### Part 3 - +Closed period

| Were the interests in the securities or contracts detailed above                              | No  |
|---|-----|
| traded during a <sup>+</sup> closed period where prior written clearance was required?        |     |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | N/A |
| If prior written clearance was provided, on what date was this provided?                      | N/A |



The CFO Solution

16 December 2019

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.